{"title":"Onkolojik hastalarda internal jügüler ven yoluyla venöz port implantasyonu- tek bir genel cerrahın deneyimi","authors":"Muharrem Öner","doi":"10.47572/muskutd.1328420","DOIUrl":null,"url":null,"abstract":"Introduction: Chemotherapy and immunotherapy are one of most used treatment modalities in oncological patients. Central venous access is preferred site of administration. Totally implantable access ports (TIAP) provide safe venous access with lower infection, malfunction problem, and less restriction for patients. Methods: 186 chemotherapy ports were inserted for oncological patients who are eligible for chemotherapy. All operations were done by a single general surgeon in Al Zahra Hospital Dubai between 2020 January- 2022 December. Single-lumen implantable port / titanium PowerPort® (Becton, Dickinson and Company, New Jersey, USA) was used for all cases. All operation were done under general anesthesia and preferred site for insertion was through right internal jugular vein with ultrasound (US) and fluoroscopy guidance. Early and late complications were recorded. Results: Success rate of access through jugular vein was 99.4 %. All patients were followed up at least 6 months. 98 patients removed their ports due to several reasons. Early complications were seen in 3 patients. 11 patients had late complications. Conclusions: US and fluoroscopy guided insertion of chemotherapy port is a safe procedure with a high-rate success. The procedure can be done by a general surgeon with low rate of early or late complications.","PeriodicalId":153630,"journal":{"name":"Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi","volume":"40 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.47572/muskutd.1328420","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Chemotherapy and immunotherapy are one of most used treatment modalities in oncological patients. Central venous access is preferred site of administration. Totally implantable access ports (TIAP) provide safe venous access with lower infection, malfunction problem, and less restriction for patients. Methods: 186 chemotherapy ports were inserted for oncological patients who are eligible for chemotherapy. All operations were done by a single general surgeon in Al Zahra Hospital Dubai between 2020 January- 2022 December. Single-lumen implantable port / titanium PowerPort® (Becton, Dickinson and Company, New Jersey, USA) was used for all cases. All operation were done under general anesthesia and preferred site for insertion was through right internal jugular vein with ultrasound (US) and fluoroscopy guidance. Early and late complications were recorded. Results: Success rate of access through jugular vein was 99.4 %. All patients were followed up at least 6 months. 98 patients removed their ports due to several reasons. Early complications were seen in 3 patients. 11 patients had late complications. Conclusions: US and fluoroscopy guided insertion of chemotherapy port is a safe procedure with a high-rate success. The procedure can be done by a general surgeon with low rate of early or late complications.